Joincare Pharmaceutical Group Industry Co., Ltd.
Clinical trials sponsored by Joincare Pharmaceutical Group Industry Co., Ltd., explained in plain language.
Chinese pharmaceutical company involved in drug research, development, and sales.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New COPD pill aims to cut Flare-Ups in half Results expected Sep 2026 (estimated)
- New shot aims to cut COPD attacks in half Results expected Sep 2027 (estimated) 🚀 Make-or-break
-
New COPD pill aims to cut Flare-Ups in half
Disease control Recruiting nowThis study tests whether a daily pill called JKN2403 can reduce serious flare-ups and improve quality of life in people with moderate-to-severe COPD. About 120 adults will take either the drug or a placebo for 24 weeks, with regular clinic visits and symptom diaries. The goal is …
Phase 2 • Sponsor: Joincare Pharmaceutical Group Industry Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New antibiotic JKN2501 enters first human tests
Disease control Recruiting nowThis early-phase trial tests the safety and tolerability of a new antibiotic called JKN2501 in 66 healthy adults in China. Participants receive either the drug or a placebo by IV infusion, and researchers monitor for side effects and how the drug moves through the body. The goal …
Phase 1 • Sponsor: Joincare Pharmaceutical Group Industry Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New Single-Dose flu drug for kids shows promise in trial
Symptom relief Recruiting nowThis study tests a new medicine called JKN2301 for children aged 2 to 11 with the flu. It is a single-dose treatment compared to the standard 5-day oseltamivir (Tamiflu) course. The goal is to see if it safely reduces flu symptoms and fever faster. About 177 children will take pa…
Phase 3 • Sponsor: Joincare Pharmaceutical Group Industry Co., Ltd • Aim: Symptom relief
Last updated Jun 27, 2026 08:13 UTC